NCT05664243View on ClinicalTrials.gov

A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 8, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Glioblastoma
Interventions
BIOLOGICAL

Autologous genetically modified gamma-delta T cells

Arm A: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with TMZ maintenance

BIOLOGICAL

Allogeneic genetically modified gamma-delta T cells

"Phase 1b and Arm B: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with D1 of TMZ 150mg/m2~Arms C: Cells will be administered on Day 1 of each of 6, 28-day cycles in combination with TMZ maintenance"

Trial Locations (5)

33612

Moffitt Cancer Center, Tampa

35294

University of Alabama at Birmingham, Birmingham

40202

University of Louisville Hospital/James Graham Brown Cancer Center, Louisville

43210

Ohio State University Wexner Medical Center- James Cancer Center, Columbus

44195

Cleveland Clinic, Cleveland

All Listed Sponsors
lead

In8bio Inc.

INDUSTRY